NCT00821535 - Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Human Immunodeficiency Virus (HIV) Infection

Interventions

DRUG

maraviroc (Selzentry, Celsentri)

12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.

Trial Locations (1)

Pfizer Investigational Site, Singapore